Prematür ejakülasyon tedavisinde güncel yaklaşımlar

AMAÇ: Prematür ejakülasyon tedavisinde güncel gelişmelerin gözden geçirilmesi GEREÇ VE YÖNTEM: Web of Science, Pubmed, Scopus ve Google Scholar gibi elektronik akademik veri tabanları aramalarından elde edilen prematür ejakülasyon tedavisi ile ilgili araştırma çalışmaları, derleme ve ilgili metinlerin gözden geçirilmesi ile hazırlanmıştır. BULGULAR: Avrupa İlaç Ajansı (EMA) kısa etkili SSRİ olan dapoksetin ve ötektik lidokain/prilokain doz ayarlamalı aerosol sprey’i PE’nin gerektiğinde tedavisi için önermektedir. Yaşam boyu PE tedavisinde PDE5i ilaçların tek başına veya SSRİ’lerle kombine şekilde kullanılması daha etkindir. Anteportal PE tedavisinde topikal anestetikler ile PD5i veya SSRİ kombinasyonları etkili olabilir. Kazanılmış PE tedavisinde psikoseksüel/davranış tedavileri ile kombine farmakolojik tedaviler yararlı olabilir. SONUÇLAR: Yaşam boyu PE tedavisinde ilk seçenek farmakoterapi olmalıdır. Özellikle anteportal PE’si olan erkeklerde periferik ve santral etkili kombine farmakolojik tedaviler yararlı olabilir. Ötektik lidokain/ prilokain doz kontrollü sprey, endikasyon dışı kullanılan SSRİ tedavisi için alternatif olabilir.

Current approaches in the treatment of prematüre ejaculation

OBJECTİVES: To review current developments in the treatment of prematüre ejaculation MATERIAL AND METHODS: Research studies, reviews, related texts related to premature ejaculation therapy obtained from electronic academic databases such as Web of Science, Pubmed, Scopus and Google Scholar were reviewed. RESULTS: The European Medicine Agency (EMA) recommends shortacting SSRI dapoxetine and eutectic lidocaine/prilocaine metered-dose aerosol spray for the on-demand treatment of PE. PDE5i drugs alone or in combination with SSRIs are more effective in the treatment of lifelong PE. Topical anesthetics and combinations of PD5i or SSRI may be effective in the treatment of anteportal PE. Pharmacological therapies combined with psychosexual/behavioral therapies may be useful in the treatment of acquired PE. CONCLUSIONS: Pharmacotherapy should be the first option for lifelong PE. Combined pharmacological therapies with peripheral and central effects may be beneficial, especially in men with anteportal PE. Eutectic lidocaine/prilocaine metered-dose aerosol spray may be an alternative for off-label SSRI treatment

PDF

___

1. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. Sex Med 2014;2:41–59. [CrossRef]
2. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. J Sex Med 2011;8:540–8. [CrossRef]
3. Gao J, Zhang X, Su P, Liu J, Xia L, Yang J, et al. Prevalence and factors associated with the complaint of premature ejaculation and the four premature ejaculation syndromes: a large observational study in China. J Sex Med 2013;10:1874–81. [CrossRef]
4. McMahon CG, Jannini EA, Serefoglu EC, Hellstrom WJ. The pathophysiology of acquired premature ejaculation. Transl Androl Urol 2016;5:434–49. [CrossRef]
5. Waldinger MD. The pathophysiology of lifelong premature ejaculation. Transl Androl Urol 2016;5:424–33. [CrossRef]
6. Corona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2015;12:2291–300. [CrossRef]
7. Clement P, Giuliano F. Physiology and Pharmacology of Ejaculation. Basic Clin Pharmacol Toxicol 2016;119(Suppl 3):18– 25. [CrossRef]
8. Gur S, Sikka SC. The characterization, current medications, and promising therapeutics targets for premature ejaculation. Andrology 2015;3:424–42. [CrossRef]
9. Andersson KE, Abdel-Hamid IA. Therapeutic targets for premature ejaculation. Maturitas 2011;70:26–33. [CrossRef]
10. Saitz TR, Serefoglu EC. Advances in understanding and treating premature ejaculation. Nat Rev Urol 2015;12:629–640. [CrossRef]
11. Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, et al. Behavioral therapies for management of premature ejaculation: a systematic review. J Sex Med 2015;3:174– 188. [CrossRef]
12. Bao B, Shang J, Wang J, Dai H, Li X, Zhang K, et al. Efficacy and safety of behavioral therapy for premature ejaculation: Protocol for a systematic review. Medicine (Baltimore) 2019;98:e14056. [CrossRef]
13. Castiglione F, Albersen M, Hedlund P, Gratzke C, Salonia A, Giuliano F. Current Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysis. Eur Urol 2016;69:904–16. [CrossRef]
14. Porst H. Premature ejaculation. In: Porst H, Reisman Y, editors. The ESSM syllabus of sexual medicine. Amsterdam: Medix Publishers; 2012. pp.547–94.
15. Martin C, Nolen H, Podolnick J, Wang R. Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going. Int J Urol 2017;24:40–50. [CrossRef]
16. Lee J. Potential Risks for the Off-Label Use of SSRIs in Premature Ejaculation (CME). J Sex Med 2010;7:2622–4. [CrossRef]
17. Koyuncu H, Serefoglu EC, Ozdemir AT, Hellstrom WJ. Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation. Int J Impot Res 2012;24:171–3. [CrossRef]
18. Porst H, Burri A. Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review. Sex Med Rev 2019;7:129–40. [CrossRef]
19. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med 2011;8:524–39. [CrossRef]
20. Park HJ, Park NC, Kim TN, Baek SR, Lee KM, Choe S. Discontinuation of dapoxetine treatment in patients with premature ejaculation: a 2-year prospective observational study. J Sex Med 2017;5:e99–105. [CrossRef]
21. Jern P, Johansson A, Piha J, Westberg L, Santtila P. Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting. Int J Impot Res 2015;27:75–80. [CrossRef]
22. Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007;39:115–8. [CrossRef]
23. Ozcan L, Polat EC, Otunctemur A, Ozbek E. Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. Int Urol Nephrol 2015;47:283–7. [CrossRef]
24. Waldinger MD. Drug treatment options for premature ejaculation. Expert Opin Pharmacother 2018;19:1077–85. [CrossRef]
25. Choi JB, Kang SH, Lee DH, Kim YS, Jeon JS, Choi WS, Kim SW. Efficacy and Safety of On Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial. J Urol 2019;201:147–53. [CrossRef]
26. Shinghal R, Barnes A, Mahar KM, Stier B, Giancaterino L, Condreay LD, et al. Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. J Sex Med 2013;10:2506–17. [CrossRef]
27. Muirhead GJ, Osterloh IH, Whaley S, van den Berg F. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. J Sex Med 2019;16:213–22. [CrossRef]
28. McMahon C, Althof S, Rosen R, et al. The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX). J Sex Med 2019; 16:1178–1187.).
29. Althof S, Osterloh IH, Muirhead GJ, et al. The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX). J Sex Med 2019; 16:1188–1198.
30. Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, Wang K. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology 2012;80:618–24. [CrossRef]
31. Yang L, Qian S, Liu H, Liu L, Pu C, Han P, Wei Q. Role of tramadol in premature ejaculation: a systematic review and metaanalysis. Urol Int 2013;91:197–205. [CrossRef]
32. Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, et al. Tramadol for premature ejaculation: a systematic review and metaanalysis. BMC Urol 2015;15:6. [CrossRef]
33. Krishnappa P, Fernandez-Pascual E, Carballido J, MartinezSalamanca JI. Sildenafil/Viagra in the treatment of premature ejaculation. Int J Impot Res 2019;31:65–70. [CrossRef]
34. Martyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, et al. Phosphodiesterase type 5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Eur Urol Focus 2017;3:119–29. [CrossRef]
35. Sun Y, Yang L, Bao Y, Liu Z, Liu L, Wei Q. Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses. World J Urol 2017;35:1817–31. [CrossRef ]
36. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. EAU Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804–14. [CrossRef]
37. Sato Y, Otani T, Amano T, Araki T, Kondou N, Matsukawa M, et al. Silodosin versus naftopidil in the treatment of premature ejaculation: a prospective multicenter trial. Int J Urol 2017;24:626– 31. [CrossRef]
38. Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology 2006;67:388–91. [CrossRef]
39. Mark KP, Kerner I. Event-level impact of Promescent on quality of sexual experience in men with subjective premature ejaculation. Int J Impot Res 2016;28:216–20. [CrossRef]
40. Porst H, Burri A. Fortacin™ Spray for the Treatment of Premature Ejaculation. Urologia 2017;84(Suppl 2):1–10. [CrossRef]
41. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo controlled study. BJU Int 2009;103:940–9. [CrossRef]
42. Liu Q, Li S, Zhang Y, Cheng Y, Fan J, Jiang L, et al. Anatomic Basis and Clinical Effect of Selective Dorsal Neurectomy for Patients with Lifelong Premature Ejaculation: A Randomized Controlled Trial. J Sex Med 2019;16:522–30. [CrossRef]
43. Anaissie J, Yafi FA, Hellstrom WJ. Surgery is not indicated for the treatment of premature ejaculation. Transl Androl Urol 2016;5:607–12. [CrossRef]
44. Althof SE. Psychosexual therapy for premature ejaculation. Transl Androl Urol 2016;5:475–81. [CrossRef]
45. Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebocontrolled clinical trial. Andrologia 2018;50:e12829. [CrossRef]
46. Tuken M, Culha MG, Serefoglu EC. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunctionDAP-SPEED Study. Int J Impot Res 2019;31:92–6. [CrossRef]
47. Atan A, Başar MM, Aydoğanli L. Comparison of the efficacy of fluoxetine alone vs. fluoxetine plus local lidocaine ointment in the treatment of premature ejaculation. Arch Esp Urol 2000;53:856–8.
48. Metin A, Kayigil O, Ahmed SI. Does lidocaine ointment addition increase fluoxetine efficacy in the same group of patients with premature ejaculation? Urol Int 2005;75:231–4. [CrossRef]
49. Dell’Atti L, Galosi AB, Ippolito C. A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation. Eur Rev Med Pharmacol Sci 2017;21:1036–40. https://www. europeanreview.org/article/12323
50. Tuken M, Kiremit MC, Serefoglu EC. On-demand Modafinil Improves Ejaculation Time and Patient-reported Outcomes in Men with Lifelong Premature Ejaculation. Urology 2016;94:139– 42. [CrossRef]
51. Sahin S, Bicer M, Yenice MG, Seker KG, Yavuzsan AH, Tugcu V. A Prospective Randomized Controlled Study to Compare Acupuncture and Dapoxetine for the Treatment of Premature Ejaculation. Urol Int 2016;97:104–11. [CrossRef]
52. Dai H, Li H, Wang J, Bao B, Yan Y, Wang B, Sun S. Effectiveness comparisons of acupuncture for premature ejaculation: Protocol for a network meta-analysis. Medicine (Baltimore) 2019;98:e14147. [CrossRef]
53. Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, et al. Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects. Drug Des Devel Ther 2017;11:713–23. [CrossRef]
54. Serefoglu EC, Hawley WR, Lasker GF, Grissom EM, Mandava SH, Sikka SC, et al. Effect of botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats. J Sex Med 2014;11:1657–63. [CrossRef]